Mylan to Acquire Remaining Stake in Indian API Subsidiary for $133 million

Mylan (Canonsburg, PA) says it plans to purchase the remaining interest in its Matrix Laboratories (Secunderabad, India) subsidiary from minority shareholders for a total of about $133 million, and also delist Matrix from the Indian stock exchanges. Mylan currently owns 71.2% of Matrix. Matrix manufactures active pharmaceutical ingredients (APIs) and finished dosage forms, and it will be delisted from the Bombay Stock Exchange, and the National Stock Exchange of India. “Purchasing the remaining interest in Matrix and delisting it from the exchanges will...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers